Search Results

ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial investigating PLX038 (PEG~SN-38) for locally-advanced or metastatic triple-negative breast cancer (TNBC).

ProLynx Inc. announced publication of a paper entitled “Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?” in BioDrugs https://doi.org/10.1007/s40259-024-00643-8.

ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors driven by MYC or MYCN amplifications.

ProLynx, Inc. announced that Richard King, MBA, has been appointed as Chief Executive Officer and as a member of the Board of Directors.

ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.

Today ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH. The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism. To achieve this, ProLynx will employ its platform half-life extension technology using its hydrogel microsphere carriers. The approved PTH replacement therapy is PTH(1-84), o

ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the National Cancer Institute (NCI). The trial combines its long-acting PEGylated SN-38, PLX038, with the Clovis Oncology PARP inhibitor, rucaparib. In preclinical studies, the PEG~SN-38 nanomolecule accumulates and is retained for long periods in tumors where it slowly releases the DNA-damaging agent SN-38.